TY - JOUR
T1 - Paediatric onset inflammatory bowel disease is a distinct and aggressive phenotype - a comparative population-based study
AU - Knudsen, Mikkel Malham
AU - Jakobsen, Christian
AU - Vester-Andersen, Marianne Kajbæk
AU - Lo, Bobby
AU - Pærregaard, Anders
AU - Vind, Ida
AU - Wewer, Anne Vibeke
PY - 2019
Y1 - 2019
N2 - Background
Paediatric onset IBD (pIBD) has been reported to be more aggressive than adult onset IBD (aIBD). Yet, a more extensive disease presentation in paediatric onset ulcerative colitis (pUC) has been the only consistent finding.
Aims
In a population‐based study, we aimed to further elucidate the differences in disease course between pIBD and aIBD.
Methods
We compared a pIBD cohort (diagnosis <15 years of age) and an aIBD cohort (diagnosis ≥18 years of age). Medical records were retrieved manually at last follow‐up, and clinical data concerning IBD phenotype and treatment were registered.
Results
We included 333 pIBD and 449 aIBD patients. Patients with pIBD more often presented with extensive disease localisation than aIBD (24%/9% of pCD/aCD with L4 disease localisation and 67%/24% of pUC/aUC with E3 disease extent). Of the patients with inflammatory disease at diagnosis, 34% and 16% of pCD and aCD patients, respectively, progressed to complicated disease over the first 7 years after diagnosis (P = .002). Patients with pUC were more often treated with systemic corticosteroids (HR: 2.0 [CI: 1.6‐2.6], P < .0001) and/or thiopurines (HR: 3.8 [CI: 2.8‐5.2], P < .0001). Lastly, pIBD patients more often received biologics (HR: 2.5 [CI: 1.8‐3.6, P < .0001] in CD and HR: 3.8 [CI: 2.1‐6.9, P < .0001] in UC) and had an increased risk of relapse (incidence rate ratio of 1.8 [CI: 1.4‐2.2, P < .0001]).
Conclusions
In this population‐based cohort study we demonstrated a more severe disease course in pIBD than in aIBD. This message should be considered by both paediatric and adult gastroenterologists when caring for pIBD patients.
AB - Background
Paediatric onset IBD (pIBD) has been reported to be more aggressive than adult onset IBD (aIBD). Yet, a more extensive disease presentation in paediatric onset ulcerative colitis (pUC) has been the only consistent finding.
Aims
In a population‐based study, we aimed to further elucidate the differences in disease course between pIBD and aIBD.
Methods
We compared a pIBD cohort (diagnosis <15 years of age) and an aIBD cohort (diagnosis ≥18 years of age). Medical records were retrieved manually at last follow‐up, and clinical data concerning IBD phenotype and treatment were registered.
Results
We included 333 pIBD and 449 aIBD patients. Patients with pIBD more often presented with extensive disease localisation than aIBD (24%/9% of pCD/aCD with L4 disease localisation and 67%/24% of pUC/aUC with E3 disease extent). Of the patients with inflammatory disease at diagnosis, 34% and 16% of pCD and aCD patients, respectively, progressed to complicated disease over the first 7 years after diagnosis (P = .002). Patients with pUC were more often treated with systemic corticosteroids (HR: 2.0 [CI: 1.6‐2.6], P < .0001) and/or thiopurines (HR: 3.8 [CI: 2.8‐5.2], P < .0001). Lastly, pIBD patients more often received biologics (HR: 2.5 [CI: 1.8‐3.6, P < .0001] in CD and HR: 3.8 [CI: 2.1‐6.9, P < .0001] in UC) and had an increased risk of relapse (incidence rate ratio of 1.8 [CI: 1.4‐2.2, P < .0001]).
Conclusions
In this population‐based cohort study we demonstrated a more severe disease course in pIBD than in aIBD. This message should be considered by both paediatric and adult gastroenterologists when caring for pIBD patients.
U2 - 10.1002/ygh2.368
DO - 10.1002/ygh2.368
M3 - Journal article
VL - 1
SP - 266
EP - 273
JO - GastroHep.
JF - GastroHep.
IS - 6
ER -